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A B S T R A C T   
Chronic kidney disease (CKD) leads to deep changes in lipid metabolism and obvious dyslipidemia. The dysre-
gulation of lipid metabolism in turn results in CKD progression and the complications of cardiovascular diseases. 
To obtain a profound insight into the associated dyslipidemia in CKD, we performed lipidomic analysis to 
measure lipid metabolites in the serum from a rat 5/6 nephrectomy (5/6 Nx) model of CKD as well as in the 
serum from CKD patients. HK-2 cells were also used to examine oxidative stress-induced sphingolipid changes. 
Totally 182 lipid species were identified in 5/6 Nx rats. We found glycerolipids, total free fatty acids, and 
sphingolipids levels were significantly upregulated in 5/6 Nx rats. The atypical sphingolipids, 1-deoxysphingo-
lipids, were significantly altered in both CKD animals and human CKD patients. The levels of 1-deoxysphingoli-
pids directly relevant to the level of oxidative stress in vivo and in vitro. These results demonstrate that 1- 
deoxysphingolipid levels are increased in CKD and this increase directly correlates with increased kidney 
oxidative stress.   
1. Introduction 
As an important public health problem, chronic kidney disease 
(CKD) damages up to 13% adults in America [1] and worldwide [2]. The 
classic biomarker used in clinics to monitor kidney function is serum 
creatinine, which is used to estimate the glomerular filtration rate and 
monitor urine output [3]. Creatinine is, however, insensitive for kidney 
injury, especially in the beginning process of disease [4], and provides 
no information on the cause and nature of renal injury, since the levels of 
creatinine are influenced by non-renal factors, including age, sex, 
nutritional status, infection, and medications [5,6]. Large efforts have 
been put into identification of new markers that are more specific to 
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renal tubular oxidative stress or can predict ‘‘subclinical’’ renal damage 
before serum creatinine elevation rather than assessing glomerular 
filtration as an endpoint. 
Lipids are small molecules representing products or intermediates of 
metabolic processes. Lipids play significant roles in cytotoxicity, signal 
transduction, and energy production. The balance of lipids intake and 
production, transport and excretion maintains the concentrations of 
various lipids in body fluids and cells. Kidney plays a central role in all 
these processes, which provides a theoretical basis for the study of lip-
idomics in nephrology [7]. Recently, increasing researches indicated 
that serum lipid profile and lipid metabolism altered markedly during 
CKD pathogenesis of in vivo and in vitro [8,9] and linked them to 
enhanced reactive oxygen species production [10,11]. Lipidomics has 
been used to determine the lipid distribution of low density lipoprotein 
(LDL), which demonstrated that triacylglycerides are significantly 
increased, and plasmenylethanolamines, cholesterol sulfate, phospha-
tidylcholines, ceramides, and sulfatides are significantly reduced in the 
advanced CKD patients [12]. 
Sphingolipids are a class of structurally highly diverse lipids that are 
fundamental components of eukaryotic cell membranes. Sphingolipid de 
novo synthesis starts with the formation of the long chain sphingoid 
base, which is the characteristic backbone of all sphingolipids. This first 
and rate-limiting step is catalyzed by the enzyme serine- 
palmitoyltransferase (SPT), which typically conjugates L-serine and 
palmitoyl-CoA [13]. Moreover, SPT shows an alternative activity with 
L-alanine, which results in the formation of an atypical category of 
1-deoxysphingolipids [14]. Due to the lack of C1-hydroxyl group of 
sphinganine, 1-deoxysphingolipid can neither form complexes (sphin-
gomyelins and glycosphingolipids) at its head group, nor proceed for 
further degradation [15]. Abnormal 1-deoxysphinglipid levels are found 
to be associated with mutations in SPT [16], certain metabolic condi-
tions [17–19] or reductions of cytochrome P450 enzymes [20]. How-
ever, the changes of serum 1-deoxysphingolipids in CKD, and the 
underlying mechanism is still unknown. 
In this study, we performed a common procedure to construct 
Sprague-Dawley rats of 5/6 Nx-induced CKD model to assess the 
changes of the associated serum sphingolipid levels. To this end, we 
analyzed serum sphingolipid levels, renal function, and renal oxidative 
stress markers in 5/6 Nx rats. In addition kidney tissue and serum 
sphingolipids were examined in CKD patients. Both animal and clinical 
data indicate that oxidative stress marker malondialdehyde (MDA) co- 
relates with the increase of 1-deoxysphingolipids in CKD. By using 
free fatty acid (FFA)-albumin overload-induced oxidative stress models 
in vivo and in vitro, oxidative stress is shown to mediate the increase of 
1-deoxysphingolipids, independent from SPT-related de novo synthesis. 
2. Materials and methods 
2.1. Animals 
Male Sprague-Dawley rats (200–220 g per rat) from Vital River 
Laboratories (Beijing, China) were randomly divided into 5/6 ne-
phrectomy (5/6 Nx) group and normal control sham group. Each group 
of rats were placed in the animal facility with a 12:12-h day and night 
cycle. The animals were allowed ad libitum to regular food (AIN93 M, 
Keao Xieli feed co. LTD, Beijing China) and water. As described previ-
ously [21], animals from CKD group received a two-stage procedure of 
5/6 nephrectomy with lateral incision to expose the retroperitoneal 
kidney. The animals from sham-operated group received the same 
incision and kidney exposure, while the kidney was kept intact. For the 
lipidomics analysis, 5 animals per group were used. In another experi-
ment, at least 6 animals were used in each group to confirm lipidomics 
results and for further analysis. All rats were sacrificed under anesthesia 
8 weeks after the second stage of surgery and kidneys were harvested. 
Half of the kidney from each animal was snap frozen in liquid nitrogen 
and stored at − 80 ◦C for RNA extraction. The other half was fixed with 
formalin for histology. For FFA-induced kidney damage experiment, a 
mild albumin overload kidney damage model was used according to 
previous studies [11,22–25], with modifications. Briefly, a 30% BSA/-
saline solution was made. For palmitate-loaded BSA, 150 μmolar 
palmitate acid was bound to 50 ml of 30% BSA to make a 1 mM BSA-FFA 
stock. Aliquots were stored at 4 ◦C until the time of injection. Groups of 
male Sprague-Dawley rats (200–220 g per rat) were randomly received 
i.p. injection with palmitate-loaded BSA (BSA-FFA, resolved in saline) or 
fatty acid-free BSA (vehicle, resolved in saline) at a dosage 1g BSA/200g 
body weight for 1 week. 
2.2. Serum and urine samples measurement 
For 24-h urine collection, rats were allowed with free access to food 
and water. Urinary H2O2 levels and urinary creatinine concentrations 
were measured with the Amplex Red H2O2 assay kit (A12214, Invi-
trogen) and the creatinine assay kit (ab65340, Abcam), respectively. 12- 
hour fasted rats were used to obtain serum samples from their tail blood. 
Serum triglyceride, cholesterol, and malondialdehyde (MDA) levels 
were measured using the triglyceride assay kit (ETGA-200, EnzyChrom, 
Aachen, Germany), the Amplex Red cholesterol assay kit (A12216, 
Invitrogen), and the Lipid Peroxidation (MDA) Assay kit (ab118970, 
Abcam), respectively. 
2.3. Renal pathology assessment and immunostaining 
In order to assess renal pathology, kidneys were embedded in 
paraffin wax following overnight fixation in 10% neutral buffer 
formalin. Fixed kidneys were sectioned into 4-μm-thick slices using a 
microtome (Leica, RM2235). Then Periodic acid-Schiff (PAS) staining 
was performed to determine the mesangial area according to the man-
ufacturer’s instruction. Masson’s trichrome staining and Methenamine 
Silver (MS) staining were performed to assess the fibrotic area using 
standard protocols. Six rats were analyzed per group. 
For immunostaining analysis, de-waxed paraffin sections (4-μm- 
thick) were hydrated, microwaved for 8–15 min in 10 mM sodium cit-
rate (pH 6.0) for antigen retrieval, and then immunostained with a 
rabbit antibody against 4-hydroxynonenal (4-HNE, ab46545, Abcam). 
Immunolabeled sections were then incubated with goat anti-rabbit 
second antibody conjugated to horseradish peroxidase and treated 
with the EnVision+ diaminobenzidine kit (DAB, Dako, Glostrup, 
Denmark) using standard protocols. 
2.4. Lipid analysis 
The lipidomic analysis was performed as described previously [26, 
27]. Quality criteria for the identified lipid metabolites were linearity 
R2>0.9 and CV<20%. For analysis of the sphingoid base profile, the 
lipids were acid/base hydrolyzed to remove the headgroups and 
N-linked fatty acid as described earlier [20,28]. Briefly, acid/-
base–hydrolyzed lipids were derivatized with ο-phthalaldehyde (OPA) 
by redissolving in 75 μl of 56.7% MeOH, 33.3% EtOH, 10% H2O and 5 μL 
OPA working solution (990 μl boric acid [3%] + 10 μl OPA [50 mg/ml in 
EtOH] + 0.5 μl 2-mercaptoethanol). For liquid chromatographic sepa-
ration of the sphingoid and deoxysphingoid base backbones, a C18 
column was used (Uptispere 120 Å, 5 μm, 125 × 2 mm, Interchim, 
Montluçon, France) coupled to a Transcend UPLC pump (Thermo, 
Reinach, BL, Switzerland). An atmospheric pressure chemical ionization 
source (APCI) was used to ionize the sphingoid and deoxysphingoid 
bases, which were then detected using a Q-Exactive hybrid quadrupole 
Orbitrap mass spectrometer (Thermo, Reinach, BL, Switzerland) run in 
full scan mode. The MS parameters used were as follows: scan range of 
m/z 120–1200, mass resolution of 140000, automatic gain control 
(ACG) target of 3.00E+06 and max injection time of 512 ms. 
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2.5. Patients 
Kidney samples were collected in the Affiliated Hospital of Shandong 
University of Traditional Chinese Medicine. This study included sixty- 
three patients with CKD, as diagnosed according to KDIGO Clinical 
Practice Guideline for the Evaluation and Management of CKD. The 
exclusion criteria were: (a) liver, thyroid, or cardiovascular (previous 
myocardial infarction, heart failure) diseases; (b) type 2 diabetes mel-
litus history; (c) high body mass index (more than 40 kg/m2); and (d) 
medication intake known to affect the test parameters. The weight 
change of participants was less than 5 kg during the last 6 months. 
Samples from 31 gender- and age-matched healthy volunteers were used 
as normal controls. Clinical and demographic data of included patients, 
such as gender, age, creatinine, and cystatin C are shown in Table 1. 
2.6. Cell culture 
HK-2 cells were maintained in K-SFM medium (17005-042, GIBCO) 
supplied with bovine pituitary extract (0.05 mg/ml, provided with the 
K-SFM kit) and human recombinant epidermal growth factor (5 ng/ml, 
provided with the K-SFM kit), plated in culture at 37 ◦C, 5% CO2. For the 
free fatty acid (FFA) treatment, cells were first starved in 0.2% FBS/ 
DMEM for 12h, cells were incubated by the addition of palmitate acid- 
bound BSA (100 μM PA) for 24 hours. BSA was used as the vehicle. 
FFA-containing medium was prepared by the conjugation of palmitate 
acid with FFA-free BSA, as previously described [29]. 
2.7. Cell staining 
FFA-treated HK-2 cells were fixed in 4% paraformaldehyde in PBS, 
and blocked with 1% BSA/PBS for 30 min following with 0.1% Triton X- 
100 treatment for 15 min. Then, the cells were incubated with primary 
antibody at 4 ◦C overnight. The cells were washed and incubated with 
secondary antibody for 1 h in the dark. After being washed, the cells 
were mounted with DAPI (Vector Laboratories) and visualized under a 
fluorescent microscope (Leica DMI6000B). For intracellular ROS 
detection, either plasmids encoding redox-sensitive GFR (roGFP plasmid 
#49435, AddGene) or CellROX green (Life Technologies) were used as 
previously described [30,31]. 
2.8. Isolation of RNA from kidney tissue and cells and quantification of 
transcript levels 
Total RNA was extracted with Trizol (Invitrogen, Waltham, MA). 
Two micrograms of total RNA were reverse transcribed using random 
primers and Superscript II reverse transcriptase (Invitrogen). First- 
strand cDNA was used as the template for real-time PCR analysis with 
primers (Applied Biosystems, CA) and TaqMan master mix. Data were 
calculated and expressed relative to levels of RNA for the housekeeping 
gene β-actin. 
2.9. Statistics 
Data are expressed as mean ± S.D. Statistical significance of differ-
ences between groups was assessed by Student’s t-test. PCA and heatmap 
visualization were performed using Metaboanalyst software. Correlation 
analysis was done using the concentrations of 1-deoxysphingolipids and 
the concentration of clinical biochemistry markers including the renal 
function parameters creatinine and cystatin c. GraphPad was used to 
perform statistical analyses. 
2.10. Study approval 
Animal protocols and experiments abided by the laws of animal 
protection and were approved by the local institutional animal com-
mittee of Shandong University of Traditional Chinese Medicine, China. 
The research from human samples was performed according to the 
Declaration of Helsinki guidelines regarding ethical principles for 
medical research involving human subjects. Written informed consent 
was provided by each patient participated in the research. The study 
protocol was approved by the Scientific Ethical Committee of Affiliated 
Hospital of Shandong University of Traditional Chinese Medicine, China 
(license number SDU2017045). 
3. Results 
3.1. General data and histological analysis of a 5/6 Nx-induced chronic 
kidney disease rat model 
Serum samples collected from rats from the 5/6 Nx group or sham 
group were first analyzed for creatinine and BUN content, the standard 
markers currently used to assess CKD. Significant, general increases in 
serum creatinine (Fig. 1 A) and BUN (Fig. 1 B) were noted in the 5/6 Nx 
group, indicating glomerular filtration damage. Histological examina-
tion of kidney tissue from 5/6 Nx rats showed clear signs of kidney 
damage in all individual, including glomeruli sclerosis, and interstitial 
fibrosis (Supplementary Fig. 1). 
3.2. Lipid abnormalities in the 5/6 nx rat model 
Next, lipidomic profiling of serum was performed. The PCA score 
plot showed a clear separation between 5/6 Nx and sham (Fig. 1C). 182 
(10 down + 172 up) lipids passed the cut-off (1.5-fold change, p < 0.02, 
and FDR<0.05) were identified (Fig. 1 D, and Supplementary Table S1 
and Supplementary Table S2). Furthermore, there were also significant 
differences in lipid subclass totals in the CKD group compared to the 
sham group (Fig. 1 E). Lipids that were significantly increased belong to 
four lipid classes: free fatty acids (FFA), triglycerides (TG), sphingolipids 
(including ceramides, Cer; hexosylceramides, CerG), and phosphati-
dylglycerol (PG). These results confirm that there are profound distur-
bance of fatty acid and triglyceride metabolism in rats with CKD, as 
previously reported in CKD patients and animal models [32,33]. Vali-
dation of serum FFA and TG confirmed increased levels of both (Fig. 1 F 
and G). The increase of sphingolipids in serum of 5/6 Nx rats was 
particularly of note. To examine changes in the sphingoid base profile, a 
targeted liquid chromatography-mass spectrometry analysis of the total 
sphingoid- and 1-deoxysphingoid base composition was performed 
(Fig. 2). Extracted sphingolipids were subjected to a serial acid and base 
hydrolysis to release the N-linked acyl and O-linked headgroup struc-
tures. Levels of canonical C18 sphingolipids represented as C18 sphin-
ganine (C18SA) (Fig. 2 A) and C18 sphingosine (C18SO) (Fig. 2 B), were 
identical between the two groups. However, the levels of the atypical 
1-deoxysphingolipids, 1-deoxysphinganine (doxSA) (Fig. 2C) and 
1-deoxysphingosine (doxSO) (Fig. 2 D), were significantly increased in 
the serum of 5/6 Nx rats compared to the sham group. 
3.3. Correlation between 1-deoxysphingolipid levels and oxidative stress 
in clinical samples 
We next investigated whether there is a correlation between serum 1- 
deoxysphinganine and clinical parameters in human CKD patients. To 
Table 1 
Clinical and demographic data of included patients.   
Normal (n = 31) CKD (n = 63) P value 
Age (years) 46.39 ± 3.231 52.06 ± 1.472 0.0729 
Gender (M/F) 15/16 30/33 >0.99 
Creatinine (μmol/L) 63.52 ± 2.126 143.2 ± 5.030 <0.0001 
Cystatin C (mg/L) 0.8697 ± 0.0261 1.615 ± 0.04073 <0.0001 
Data are means ± SD. Abbreviations: M, male; F, female; CKD, chronic kidney 
disease. 
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distinguish the lipid changes in CKD caused from systemic disorders, 
patients with amyloidosis, diabetes, systemic lupus erythematosus, etc. 
were excluded from the study. Table 1 shows the clinical and de-
mographic data of patients participated in this study. No significant 
differences were found in age and gender between patients with CKD 
and healthy controls. Serum creatinine and cystatin C were significantly 
higher in patients with CKD compared to the healthy controls. The 
kidneys from CKD patients showed signs of glomerulisclerosis, fibrosis 
and oxidative stress (Fig. 3 A). Blood levels of MDA, C18SA, doxSA, and 
doxSO were also increased in the CKD group (Fig. 3 B). 
Fig. 1. Lipidomics analysis of serum lipids from sham and 5/6 Nx rats. (A) Serum creatinine and (B) serum BUN from sham and 5/6 Nx groups. n = 6/group. Data 
are mean ± SD, student’s t-test. (C) Principal component analysis (PCA) score plot of lipidomics profiles of the two groups (n = 5/group). (D) Volcano plot identified 
lipid species passing the cut-off (1.5-fold change and p < 0.02). (E) Heatmap of clustered lipids from sham and 5/6 Nx rats. Serum levels of (F) fatty acids (FA) and 
(G) triglycerides (TG) from different groups. n = 6/group. Data are means ± SD, student’s t-test. PS, phosphatidylserine; FA, fatty acids; TG, triglycerides; Cer, 
ceramide; PG, phosphatidylglycerol; CerG, hexosylceramide; PI, phosphatidylinositol; PC, phosphatidylcholine; PE, phosphatidylethanolamine; SM, sphingomyelin. 
Fig. 2. Sphingoid base profile of total serum sphingolipids. Quantitative analysis of serum (A) C18SA, (B) C18SO, (C) doxSA, and (D) doxSO from sham and 5/6 Nx 
groups. The profile reflects the total sphingoid base composition of serum sphingolipids measured after hydrolysis. C18SA, C18 sphinganine; C18SO, C18 sphin-
gosine; doxSA, 1-deoxysphinganine; doxSO, 1-deoxysphingosine. n = 6/group. Data are means ± SD, student’s t-test. 
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The relationships between serum concentrations of C18- 
sphingolipids or 1-deoxysphingolipids and the oxidative stress marker 
MDA and glomerular filtration markers (creatinine and cystatin C) in 
healthy subjects and CKD patients are illustrated in Table 2. Serum C18 
sphingolipids were not co-related with either MDA or glomerular 
filtration markers (Table 2 and Fig. 4 A and B). Both 1-deoxysphinganine 
and 1-deoxysphingosine showed significant positive correlations with 
MDA in CKD patients but not in healthy subjects (Table 2 and Fig. 4 C 
and D). There was a significant negative correlation between serum 1- 
deoxysphinganine and Cystatin C (Table 2). There were no significant 
negative correlations between serum 1-deoxyshingolipids with creati-
nine. Interestingly, when the creatinine levels were translated into 
eGFR, serum 1-deoxysphingosine was positively correlated with eGFR 
levels in CKD patients. This indicates a positive relationship between the 
extent of oxidative stress and serum 1-deoxysphingolipid levels, but not 
with canonical C18-sphingolipids in CKD patients. 
Fig. 3. CKD patients show higher oxidative stress and increased 1-deoxysphingolipid levels. (A) Representative images showing (a and d) Methenamine Silver (MS) 
staining, (b and e) Periodic acid–Schiff (PAS) staining and (c and f) immunostaining for 4-HNE on renal biopsies from (a, c, and e) normal and (b, d, and f) CKD 
patients (scale bar 20 μm for MS staining and PAS staining; scale bar 100 μm for 4-HNE staining). (g to i) Quantitative analysis of (g) MS staining, (h) PAS staining, 
and (i) immunostaining for 4-HNE. (B to F) Violin plot analysis showing the mean and variance differences in serum (B) MDA, (C) C18SA, (D) C18SO, (E) doxSA, and 
(F) doxSO between healthy subjects and CKD patients. C18SA, C18 sphinganine; C18SO, C18 sphingosine; doxSA, 1-deoxysphinganine; doxSO, 1-deoxysphingosine. 
Data are means ± SD, student’s t-test. 
Table 2 
1-deoxysphingolipids significantly associated with serum oxidative stress marker MDA.   
C18SA dependent variable C18SO dependent variable doxSA dependent variable doxSO dependent variable  
R p value r p value r p value r p value 
Creatinine -0.2007 0.1148 -0.2659 0.1772 -0.2183 0.0856 -0.2157 0.0896 
Cystatin C -0.0452 0.7227 0.0215 0.8662 -0.2623 0.0362 -0.2434 0.0526 
eGFR 0.1316 0.3039 0.2184 0.0855 0.1975 0.1207 0.2822 0.0251 
MDA 0.0316 0.8024 -0.0300 0.8139 0.2619 0.0183 0.2383 0.0290 
Data are means ± SD. Abbreviations: eGFR, estimated glomerular filtration rate; MDA, malondialdehyde. 
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3.4. Increased serum 1-deoxysphingolipid levels are a marker of FFA- 
induced tubule oxidative stress in a chronic kidney disease rat model 
Since fatty acids are the preferred energy source for proximal tubular 
cells, excessive fatty acid supply induces oxidative stress and mito-
chondrial dysfunction, which result in reduced fatty acid oxidation and 
abnormal lipid metabolism [8]. In human CKD and an animal model of 
5/6 Nx-induced CKD, increased urinary albumin and albumin-bound 
FFA may increase the exposure of FFA to proximal tubules and result 
in tubular damage, oxidative stress, and mitochondrial dysfunction [11, 
34,35]. To evaluate if increased 1-deoxysphingolipid levels are a result 
of increased FFA exposure and subsequent abnormal lipid oxidation and 
oxidative stress in proximal tubules, rats were i.p. injected with 
BSA-bound FFA. Urinary H2O2 and serum levels of MDA were signifi-
cantly increased by 1.5 to 2-fold in BSA-FFA compared to vehicle lit-
termates (Fig. 5 A and B). A significant increase of lipid peroxidation was 
detected in BSA-FFA rats as examined by immunostaining for 4-HNE, 
which was closely associated with the severity of proximal tubule 
Fig. 4. 1-Deoxysphingolipid levels correlated with oxidative stress marker MDA. Correlation analysis between serum MDA and serum (A) C18SA, (B) C18SO, (C) 
doxSA, and (D) doxSO in CKD patients. C18SA, C18 sphinganine; C18SO, C18 sphingosine; doxSA, 1-deoxysphinganine; doxSO, 1-deoxysphingosine. 
Fig. 5. FFA overload in vivo induces oxidative stress and results in increased serum levels of 1-deoxysphingolipids. Quantitative analysis of (A) urinary H2O2 and (B) 
serum MDA from rats after vehicle (BSA) and FFA (BSA-bound FFA) injections. n = 6/group. Data are means ± SD, student’s t-test. Representative images showing 
(C) immunostaining for 4-HNE on renal sections from (a) vehicle and (b) FFA groups (scale bar 50 μm). (c) Quantitative analysis of immunostaining for 4-HNE. (D 
and E) Quantitative analysis of serum (D) C18 sphingoid bases, and (E) deoxysphingoid bases from vehicle and FFA groups. C18SA, C18 sphinganine; C18SO, C18 
sphingosine; doxSA, 1-deoxysphinganine; doxSO, 1-deoxysphingosine. n = 6/group. Data are means ± SD, student’s t-test. (F and G) mRNA level of (F) SPTLC2 and 
(G) SPTLC3 in the kidney of rats with different treatments. n = 6/group. Data are means ± SD, student’s t-test. 
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oxidative stress (Fig. 5C). There was also a resulting increase in both 
1-deoxysphinganine and 1-deoxysphingosine but not of the canonical 
sphingolipids (C18SA and C18SO) in the serum of BSA-FFA group (Fig. 5 
D and E). In addition, mRNA expression of SPTLC2 (Serine Palmitoyl-
transferase Long Chain Base Subunit 2) and SPTLC3 (Serine Palmitoyl-
transferase Long Chain Base Subunit 3), the two main sphingolipid de 
novo synthesis enzymes, were not changed between treatment groups 
(Fig. 5 F and G), indicating that increased 1-deoxysphingolipids are not a 
direct conversion from fatty acids. 
3.5. Oxidative stress induces 1-deoxysphingolipid levels in vitro 
To examine whether increased oxidative stress causes the induction 
of 1-deoxysphingolipid levels in vitro, HK-2 proximal tubule cells were 
treated with free fatty acid-bound BSA. The intracellular levels of 
oxidative stress, indicated by CellROX or roGFP probe, were signifi-
cantly induced by FFA treatment (Fig. 6 A, B and C). The oxidative stress 
induced by FFA resulted in an induction of 1-deoxysphingoid bases but 
not of the canonical C18 sphingoid bases in HK-2 cells (Fig. 6 D and E). 
In consistent with in vivo data, the mRNA expression of SPTLC2 and 
SPTLC3 were not changed between treatment groups (Fig. 6 F). 
4. Discussion 
Several lipid classes play an important role in biomarker research 
and risk stratification of cardiovascular disease [36], diabetes [37], and 
kidney disorders [38–40]. The lipid categories associate with bio-
markers in CKD including glycerolipids, fatty acids, sphigolipids and 
sterols. Our results confirm that there are profound disturbance of tri-
glyceride and fatty acid metabolism in patients with CKD, as previously 
reported in animal models and CKD patients [32,33]. The present study 
demonstrated that serum concentrations of the atypical 1-deoxysphingo-
lipids were elevated in CKD patients compared to healthy subjects. 
Furthermore, the levels of serum 1-deoxysphingolipid correlated with 
oxidative stress marker MDA levels in CKD patients. 
Elevated intracellular levels of reactive oxygen species (ROS) play a 
major role in the pathogenesis of CKD [41]. To avoid cellular damage, 
normal kidney cell function relies on the optimal amount of ROS. Extra 
intracellular levels of ROS could cause DNA, lipids, and proteins 
oxidation. Oxidative stress is a common feature in CKD patients [42,43], 
and associated with disruptions in lipid metabolism that results in 
upregulated glycerophosphoethanolamines and bile acids levels [44]. 
The important role of oxidative stress in CKD is well recognized, while 
Fig. 6. FFA overload in vitro induces oxidative stress and results in increased intracellular levels of 1-deoxysphingolipids. (A) Representative images of (a and b) 
CellROX staining and (c and d) cytosolic ROS sensing in HK-2 cells after different treatments (scale bar 100 μm). (B and C) Quantitative analysis of intracellular (B) 
ROS, and (C) roGPF from vehicle and FFA groups. n = 6/group. Data are means ± SD, ANOVA test. (D and E) Quantitative analysis of intracellular (D) C18 sphingoid 
bases, and (E) deoxysphingoid bases from vehicle and FFA groups. C18SA, C18 sphinganine; C18SO, C18 sphingosine; doxSA, 1-deoxysphinganine; doxSO, 1-deox-
ysphingosine. n = 6/group. Data are means ± SD, student’s t-test. (F) mRNA level of SPTLC2 and SPTLC3 in the HK-2 cells with different treatments. n = 6/group. 
Data are means ± SD, student’s t-test. 
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there are limited clinical tools to monitor oxidative stress. Levels of the 
oxidative stress markers methionine sulfoxide, methionine 
sulfoxide-to-methionine ratio [45,46], and malonedialdehyde [47] have 
already been analyzed by metabolomics. It is very difficult for quanti-
tative analysis of oxidative stress in order to meet the special conditions 
for pre-analysis. Oxidative stress in CKD was demonstrated to be asso-
ciated with marked alteration of serum concentrations of different lipids 
[32,48]. In the present study we found that FFA-induced oxidative stress 
results in increased 1-deoxysphingolipid levels both in vivo and in vitro. 
Furthermore, the correlation between 1-deoxysphingolipid levels and 
oxidative stress marker, MDA, was significant in serum from CKD pa-
tients. Given the nature that 1-deoxysphingolipids are hardly degraded 
in the body once it is synthesized as it can not be phosphorylated by 
sphingosine kinase and degraded by S1P lyase, serum 1-deoxysphingoli-
pids could be used as a useful marker for kidney oxidative stress in CKD 
patients. 
A number of uremic toxins (including fatty acids) are found to be 
increased in CKD and are potent oxidative stress inducers through 
impairing mitochondrial function [49–51]. Considering the large num-
ber of uremic toxins, 1-deoxysphingolipids could contribute partially to 
oxidative stress, as examined by recent publications [28,52]. However, 
several key points indicate that the increases of 1-deoxyphingolipid 
levels in CKD are independent to oxidative stress: (1) Because of the 
absence of the C1 hydroxyl group, 1-deoxysphingolipids can neither be 
converted to sphingomyelin through sphingomyelin phosphodiesterase 
(SMase), nor be degraded through sphingosine kinase (SPHK) [53]. 
Although increase of oxidants regulate enzyme activities of SMase [54, 
55] and SPHK [56,57] and their metabolites [58], such enzymatic 
pathways are not related to 1-deoxysphingolipid production; (2) A 
number of reports suggest that lipid accumulation in kidney could be 
harmful and is referred to as lipotoxicity [59]. It is still under debate 
whether lipids per se are toxic, but it is clear that intra-renal lipid 
accumulation can cause characteristics of renal oxidative stress status 
[60]. The reason why 1-deoxysphingolipids are increased in CKD could 
be due to the dyslipidemia-induced oxidative stress and defective 
mitochondrial fatty acid oxidation which oftenly occurs in CKD [61,62], 
resulting in an accumulation of intracellular fatty acids; (3) Among 
patients with diabetic nephropathy, hypertensive nephropathy, and 
chronic nephritis, serum levels of serine and glycine are decreased 
compared with healthy controls [63]. These results indicate that serine 
deficiency increases lipid accumulation in ESRD patients. Serine defi-
ciency is also linked with altered glutathione metabolism and mito-
chondrial dysfunction (oxidative stress), as well as increased 
1-deoxysphingolipid de novo synthesis [64]; (4) In parallel, reduced 
expression of cytochrome P450 genes and gene products (i.e., reduced 
mRNA and protein, or reduced protein with no change in mRNA) in 
several animal models of CKD were observed [65]. Although the precise 
mechanism(s) of the down-regulation of CYP genes in these CKD models 
remains unknown, ex vivo studies showed that uremic human serum 
obtained from patients with end-stage renal disease led to a decrease in 
protein expression and activity for all the major xenobiotic-metabolizing 
CYPs. Such decreased cytochrome enzymes may result in reduced 
degradation of 1-deoxysphingolipids, which was demonstrated in our 
previous study in NAFLD [20,28]; Taken together, dyslipidemia-induces 
oxidative stress and in parallel de novo synthesis of 1-deoxysphingoli-
pids due to fatty acid accumulation and serine deficiency which is 
often seen in CKD. Furthermore, decreased cytochrome P450 enzymes 
may result in less degradation of 1-deoxysphingolipids and accelerate 
the progression of CKD through the direct lipotoxic effects of 1-deoxy-
sphingolipids on renal cells. 
The reason for increased circulating 1-deoxysphigolipids in CKD still 
remains unclear. When an uncontrolled influx of free fatty acids were 
flowing into the proximal tubules present in massive proteinuria, FFA 
not only promote oxidative stress and nephrotoxicity, but could be also 
transported to the ER where they could be used for de novo 1-deoxy-
sphingolipid synthesis [66,67], which may in turn increase levels of 
1-deoxysphingolipids in the blood. Dyslipidemic patients benefit from 
the 1-deoxyshingolipids-lowering effects of fenofibrate treatment [68], 
which is also commonly used in the treatment against CKD. Several 
recent clinical studies, including subanalyses of the FIELD (the Fenofi-
brate Intervention and Event Lowering in Diabetes Study) and DAIS 
(Diabetes Atherosclerosis Intervention Study) trials, support the urinary 
albumin-lowering effects of fenofibrate [69–71]. However, as fibrates 
can be associated with a rise in blood creatinine levels, their effect on 
oxidative stress-related renal dysfunction is less obvious. Furthermore, 
although C18 sphingolipids and 1-deoxysphingolipids could both be de 
novo synthesized from palmitate acid, changes of 1-deoxysphingolipid 
levels seem to be independent to C18 sphingolipids and de novo syn-
thesis through SPTs, because (1) myriocin, a potent inhibitor of sphin-
golipid de novo synthesis, has no effects on 1-deoxysphingolipid de novo 
synthesis [72]; and (2) FXR, a nuclear receptor which regulates hepa-
tocyte lipid homeostasis, induces 1-deoxysphingolipids degradation but 
does not change C18 sphingolipid levels [73]. Great efforts are still 
needed to further determine the exact molecular signaling mechanisms 
underlying the elevation of circulating 1-deoxysphingolipid levels. 
The relations between glomerular filtration and increased serum 1- 
deoxysphingolipid levels are still not clear. In present study, doxSA is 
negatively correlated with Cystatin C, however, doxSO is positively 
correlated with eGFR. Since sphingolipids are constituents of lipopro-
teins which are too large to pass the glomeruli [74], the elimination way 
of sphingolipids could be different to Cystatin C, which makes it difficult 
to directly compare the relationships between those parameters. 
Furthermore, since eGFR also depends on gender, age and ethnics, the 
observed corrections could also be indirect. Further studies regarding to 
CKD stages, real GFR (assessed from clearance measurements), and 
other factors, such as gender and age, need to be done. 
Collectively, our experimental model indicates that the increased 
serum level of 1-deoxysphingolipids reflects a stress, such as FFA over-
load or protein-bound FFA-induced oxidative stress, on the proximal 
tubules. The clinical results support this hypothesis and show that serum 
1-deoxysphingolipids might be useful clinical markers for CKD. These 
results provide a novel possibility for applying for the clinical implica-
tions of sphingolipid levels in the oxidative stress status of CKD. 
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T. Stoeckli, G. Nicholson, F. Eichler, R.H. Brown, A. von Eckardstein, 
T. Hornemann, Hereditary sensory neuropathy type 1 is caused by the 
accumulation of two neurotoxic sphingolipids, J. Biol. Chem. 285 (15) (2010) 
11178–11187. 
[15] M.A. Lone, T. Santos, I. Alecu, L.C. Silva, T. Hornemann, 1-Deoxysphingolipids, 
Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1864 (4) (2019) 512–521. 
[16] A. Penno, M.M. Reilly, H. Houlden, M. Laura, K. Rentsch, V. Niederkofler, E. 
T. Stoeckli, G. Nicholson, F. Eichler, R.H. Brown Jr., A. von Eckardstein, 
T. Hornemann, Hereditary sensory neuropathy type 1 is caused by the 
accumulation of two neurotoxic sphingolipids, J. Biol. Chem. 285 (15) (2010) 
11178–11187. 
[17] Y. Yoshimine, H. Uto, K. Kumagai, S. Mawatari, S. Arima, R. Ibusuki, K. Mera, 
T. Nosaki, S. Kanmura, M. Numata, T. Tamai, A. Moriuchi, H. Tsubouchi, A. Ido, 
Hepatic expression of the Sptlc3 subunit of serine palmitoyltransferase is 
associated with the development of hepatocellular carcinoma in a mouse model of 
nonalcoholic steatohepatitis, Oncol. Rep. 33 (4) (2015) 1657–1666. 
[18] R.A. Zuellig, T. Hornemann, A. Othman, A.B. Hehl, H. Bode, T. Güntert, O. 
O. Ogunshola, E. Saponara, K. Grabliauskaite, J.-H. Jang, U. Ungethuem, Y. Wei, 
A. von Eckardstein, R. Graf, S. Sonda, Deoxysphingolipids, novel biomarkers for 
type 2 diabetes, are cytotoxic for insulin-producing cells, Diabetes 63 (4) (2014) 
1326–1339. 
[19] A. Othman, M.F. Rütti, D. Ernst, C.H. Saely, P. Rein, H. Drexel, C. Porretta- 
Serapiglia, G. Lauria, R. Bianchi, A. von Eckardstein, T. Hornemann, Plasma 
deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome? 
Diabetologia 55 (2) (2012) 421–431. 
[20] Z. Gai, T. Gui, I. Alecu, M.A. Lone, T. Hornemann, Q. Chen, M. Visentin, C. Hiller, 
S. Hausler, G.A. Kullak-Ublick, Farnesoid X receptor activation induces the 
degradation of hepatotoxic 1-deoxysphingolipids in non-alcoholic fatty liver 
disease, Liver Int. : Off. J. Int. Assoc.e Stud. Liver 40 (4) (2019) 844–859. 
[21] Z. Gai, L. Chu, C. Hiller, D. Arsenijevic, C.A. Penno, J.P. Montani, A. Odermatt, G. 
A. Kullak-Ublick, Effect of chronic renal failure on the hepatic, intestinal, and renal 
expression of bile acid transporters, Am. J. Physiol. Ren. Physiol. 306 (1) (2014) 
F130–F137. 
[22] A.A. Eddy, H. Kim, J. Lopez-Guisa, T. Oda, P.D. Soloway, Interstitial fibrosis in 
mice with overload proteinuria: deficiency of TIMP-1 is not protective, Kidney Int. 
58 (2) (2000) 618–628. 
[23] Y. Takagaki, S. Shi, M. Katoh, M. Kitada, K. Kanasaki, D. Koya, Dipeptidyl 
peptidase-4 plays a pathogenic role in BSA-induced kidney injury in diabetic mice, 
Sci. Rep. 9 (1) (2019) 7519. 
[24] D.A. Ishola Jr., D.M. van der Giezen, B. Hahnel, R. Goldschmeding, W. Kriz, H. 
A. Koomans, J.A. Joles, In mice, proteinuria and renal inflammatory responses to 
albumin overload are strain-dependent, Nephrol. Dial. Transplant. 21 (3) (2006) 
591–597, official publication of the European Dialysis and Transplant Association - 
European Renal Association. 
[25] M.E. Thomas, N.J. Brunskill, K.P. Harris, E. Bailey, J.H. Pringle, P.N. Furness, 
J. Walls, Proteinuria induces tubular cell turnover: a potential mechanism for 
tubular atrophy, Kidney Int. 55 (3) (1999) 890–898. 
[26] R.M. Pellegrino, A. Di Veroli, A. Valeri, L. Goracci, G. Cruciani, LC/MS lipid 
profiling from human serum: a new method for global lipid extraction, Anal. 
Bioanal. Chem. 406 (30) (2014) 7937–7948. 
[27] M. Narvaez-Rivas, Q. Zhang, Comprehensive untargeted lipidomic analysis using 
core-shell C30 particle column and high field orbitrap mass spectrometer, 
J. Chromatogr., A 1440 (2016) 123–134. 
[28] I. Alecu, A. Othman, A. Penno, E.M. Saied, C. Arenz, A. von Eckardstein, 
T. Hornemann, Cytotoxic 1-deoxysphingolipids are metabolized by a cytochrome 
P450-dependent pathway, J. Lipid Res. 58 (1) (2017) 60–71. 
[29] Z. Gai, T. Gui, C. Hiller, G.A. Kullak-Ublick, Farnesoid X receptor protects against 
kidney injury in uninephrectomized obese mice, J. Biol. Chem. 291 (5) (2016) 
2397–2411. 
[30] G.B. Waypa, J.D. Marks, R. Guzy, P.T. Mungai, J. Schriewer, D. Dokic, P. 
T. Schumacker, Hypoxia triggers subcellular compartmental redox signaling in 
vascular smooth muscle cells, Circ. Res. 106 (3) (2010) 526–535. 
[31] Z. Gai, E. Krajnc, S.L. Samodelov, M. Visentin, G.A. Kullak-Ublick, Obeticholic acid 
ameliorates valproic acid-induced hepatic steatosis and oxidative stress, Mol. 
Pharmacol. 97 (5) (2020) 314–323. 
[32] D.Q. Chen, H. Chen, L. Chen, N.D. Vaziri, M. Wang, X.R. Li, Y.Y. Zhao, The link 
between phenotype and fatty acid metabolism in advanced chronic kidney disease, 
Nephrol. Dial. Transplant. 32 (7) (2017) 1154–1166, official publication of the 
European Dialysis and Transplant Association - European Renal Association. 
[33] H. Chen, L. Chen, D. Liu, D.Q. Chen, N.D. Vaziri, X.Y. Yu, L. Zhang, W. Su, X. Bai, Y. 
Y. Zhao, Combined clinical phenotype and lipidomic analysis reveals the impact of 
chronic kidney disease on lipid metabolism, J. Proteome Res. 16 (4) (2017) 
1566–1578. 
[34] M.E. Thomas, K.P. Harris, J. Walls, P.N. Furness, N.J. Brunskill, Fatty acids 
exacerbate tubulointerstitial injury in protein-overload proteinuria, Am. J. Physiol. 
Ren. Physiol. 283 (4) (2002) F640–F647. 
[35] M. Arici, R. Chana, A. Lewington, J. Brown, N.J. Brunskill, Stimulation of proximal 
tubular cell apoptosis by albumin-bound fatty acids mediated by peroxisome 
proliferator activated receptor-gamma, J. Am. Soc. Nephrol. : JASN (J. Am. Soc. 
Nephrol.) 14 (1) (2003) 17–27. 
[36] P. Wurtz, A.S. Havulinna, P. Soininen, T. Tynkkynen, D. Prieto-Merino, T. Tillin, 
A. Ghorbani, A. Artati, Q. Wang, M. Tiainen, A.J. Kangas, J. Kettunen, 
J. Kaikkonen, V. Mikkila, A. Jula, M. Kahonen, T. Lehtimaki, D.A. Lawlor, T. 
R. Gaunt, A.D. Hughes, N. Sattar, T. Illig, J. Adamski, T.J. Wang, M. Perola, 
S. Ripatti, R.S. Vasan, O.T. Raitakari, R.E. Gerszten, J.P. Casas, N. Chaturvedi, 
M. Ala-Korpela, V. Salomaa, Metabolite profiling and cardiovascular event risk: a 
prospective study of 3 population-based cohorts, Circulation 131 (9) (2015) 
774–785. 
[37] R. Wang-Sattler, Z. Yu, C. Herder, A.C. Messias, A. Floegel, Y. He, K. Heim, 
M. Campillos, C. Holzapfel, B. Thorand, H. Grallert, T. Xu, E. Bader, C. Huth, 
K. Mittelstrass, A. Doring, C. Meisinger, C. Gieger, C. Prehn, W. Roemisch-Margl, 
M. Carstensen, L. Xie, H. Yamanaka-Okumura, G. Xing, U. Ceglarek, J. Thiery, 
G. Giani, H. Lickert, X. Lin, Y. Li, H. Boeing, H.G. Joost, M.H. de Angelis, 
W. Rathmann, K. Suhre, H. Prokisch, A. Peters, T. Meitinger, M. Roden, H. 
E. Wichmann, T. Pischon, J. Adamski, T. Illig, Novel biomarkers for pre-diabetes 
identified by metabolomics, Mol. Syst. Biol. 8 (2012) 615. 
[38] O.N. Goek, C. Prehn, P. Sekula, W. Romisch-Margl, A. Doring, C. Gieger, M. Heier, 
W. Koenig, R. Wang-Sattler, T. Illig, K. Suhre, J. Adamski, A. Kottgen, C. Meisinger, 
Metabolites associate with kidney function decline and incident chronic kidney 
disease in the general population, Nephrol. Dial. Transplant. 28 (8) (2013) 
2131–2138, official publication of the European Dialysis and Transplant 
Association - European Renal Association. 
[39] E. Albrecht, M. Waldenberger, J. Krumsiek, A.M. Evans, U. Jeratsch, M. Breier, 
J. Adamski, W. Koenig, S. Zeilinger, C. Fuchs, N. Klopp, F.J. Theis, H.E. Wichmann, 
K. Suhre, T. Illig, K. Strauch, A. Peters, C. Gieger, G. Kastenmuller, A. Doering, 
C. Meisinger, Metabolite profiling reveals new insights into the regulation of serum 
urate in humans, Metabolomics, Off. J. Metabol. Soc. 10 (1) (2014) 141–151. 
[40] O.N. Goek, A. Doring, C. Gieger, M. Heier, W. Koenig, C. Prehn, W. Romisch-Margl, 
R. Wang-Sattler, T. Illig, K. Suhre, P. Sekula, G. Zhai, J. Adamski, A. Kottgen, 
C. Meisinger, Serum metabolite concentrations and decreased GFR in the general 
population, Am. J. Kidney Dis. : Off. J. Nat. Kidney Found. 60 (2) (2012) 197–206. 
[41] M. Irazabal, V. Torres, Reactive oxygen species and redox signaling in chronic 
kidney disease, Cells 9 (6) (2020). 
[42] N.D. Vaziri, Oxidative stress in uremia: nature, mechanisms, and potential 
consequences, Semin. Nephrol. 24 (5) (2004) 469–473. 
[43] F. Locatelli, B. Canaud, K.U. Eckardt, P. Stenvinkel, C. Wanner, C. Zoccali, 
Oxidative stress in end-stage renal disease: an emerging threat to patient outcome, 
Nephrol. Dial. Transplant. 18 (7) (2003) 1272–1280, official publication of the 
European Dialysis and Transplant Association - European Renal Association. 
T. Gui et al.                                                                                                                                                                                                                                      
Free Radical Biology and Medicine 164 (2021) 139–148
148
[44] H. Chen, G. Cao, D.Q. Chen, M. Wang, N.D. Vaziri, Z.H. Zhang, J.R. Mao, X. Bai, Y. 
Y. Zhao, Metabolomics insights into activated redox signaling and lipid metabolism 
dysfunction in chronic kidney disease progression, Redox Biol. 10 (2016) 168–178. 
[45] R. Mashima, T. Nakanishi-Ueda, Y. Yamamoto, Simultaneous determination of 
methionine sulfoxide and methionine in blood plasma using gas chromatography- 
mass spectrometry, Anal. Biochem. 313 (1) (2003) 28–33. 
[46] M. Breier, S. Wahl, C. Prehn, M. Fugmann, U. Ferrari, M. Weise, F. Banning, 
J. Seissler, H. Grallert, J. Adamski, A. Lechner, Targeted metabolomics identifies 
reliable and stable metabolites in human serum and plasma samples, PloS One 9 
(2) (2014), e89728. 
[47] I. Fonseca, H. Reguengo, M. Almeida, L. Dias, L.S. Martins, S. Pedroso, J. Santos, 
L. Lobato, A.C. Henriques, D. Mendonca, Oxidative stress in kidney 
transplantation: malondialdehyde is an early predictive marker of graft 
dysfunction, Transplantation 97 (10) (2014) 1058–1065. 
[48] Y.Y. Zhao, H.L. Wang, X.L. Cheng, F. Wei, X. Bai, R.C. Lin, N.D. Vaziri, 
Metabolomics analysis reveals the association between lipid abnormalities and 
oxidative stress, inflammation, fibrosis, and Nrf2 dysfunction in aristolochic acid- 
induced nephropathy, Sci. Rep. 5 (2015) 12936. 
[49] T. Niwa, Role of indoxyl sulfate in the progression of chronic kidney disease and 
cardiovascular disease: experimental and clinical effects of oral sorbent AST-120, 
Ther. Apher. Dial. 15 (2) (2011) 120–124. 
[50] M. Yisireyili, H. Shimizu, S. Saito, A. Enomoto, F. Nishijima, T. Niwa, Indoxyl 
sulfate promotes cardiac fibrosis with enhanced oxidative stress in hypertensive 
rats, Life Sci. 92 (24–26) (2013) 1180–1185. 
[51] S. Schmidt, T.H. Westhoff, P. Krauser, W. Zidek, M. van der Giet, The uraemic toxin 
phenylacetic acid increases the formation of reactive oxygen species in vascular 
smooth muscle cells, Nephrol. Dial. Transplant. 23 (1) (2008) 65–71, official 
publication of the European Dialysis and Transplant Association - European Renal 
Association. 
[52] M.A. Lauterbach, V. Saavedra, M.S.J. Mangan, A. Penno, C. Thiele, E. Latz, 
L. Kuerschner, 1-Deoxysphingolipids cause autophagosome and lysosome 
accumulation and trigger NLRP3 inflammasome activation, Autophagy 24 (2020) 
1–15. 
[53] A.C. Carreira, T.C. Santos, M.A. Lone, E. Zupančič, E. Lloyd-Evans, R.F.M. de 
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